BRANCACCIO, GIUSEPPINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.583
AS - Asia 4.772
EU - Europa 2.231
SA - Sud America 945
AF - Africa 864
OC - Oceania 86
Continente sconosciuto - Info sul continente non disponibili 27
Totale 16.508
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.139
SG - Singapore 1.470
CN - Cina 816
BR - Brasile 600
VN - Vietnam 583
HK - Hong Kong 564
IT - Italia 427
DE - Germania 179
FR - Francia 175
GB - Regno Unito 173
IN - India 153
PL - Polonia 149
BD - Bangladesh 133
FI - Finlandia 122
NL - Olanda 120
RU - Federazione Russa 109
JP - Giappone 84
AR - Argentina 78
TR - Turchia 78
IQ - Iraq 74
SA - Arabia Saudita 60
ZA - Sudafrica 54
ID - Indonesia 53
KR - Corea 53
PK - Pakistan 53
CA - Canada 52
SE - Svezia 49
ES - Italia 48
PH - Filippine 48
PY - Paraguay 44
UA - Ucraina 44
UZ - Uzbekistan 44
EC - Ecuador 43
MX - Messico 43
IE - Irlanda 40
CO - Colombia 37
CZ - Repubblica Ceca 35
EG - Egitto 35
AT - Austria 34
RO - Romania 34
CL - Cile 32
LY - Libia 32
JO - Giordania 31
TN - Tunisia 31
MA - Marocco 29
MZ - Mozambico 29
PE - Perù 29
TH - Thailandia 29
ET - Etiopia 28
GR - Grecia 28
KE - Kenya 28
LB - Libano 28
VE - Venezuela 28
BB - Barbados 27
CI - Costa d'Avorio 27
BA - Bosnia-Erzegovina 26
HN - Honduras 26
HR - Croazia 26
LV - Lettonia 26
MY - Malesia 26
PT - Portogallo 26
AE - Emirati Arabi Uniti 25
AM - Armenia 25
MK - Macedonia 25
UG - Uganda 25
BJ - Benin 24
DO - Repubblica Dominicana 24
EE - Estonia 24
KG - Kirghizistan 24
MD - Moldavia 24
PA - Panama 24
PS - Palestinian Territory 24
RS - Serbia 24
AZ - Azerbaigian 23
BE - Belgio 23
NP - Nepal 23
SK - Slovacchia (Repubblica Slovacca) 23
SN - Senegal 23
TJ - Tagikistan 23
YT - Mayotte 23
AO - Angola 22
CH - Svizzera 22
CM - Camerun 22
GA - Gabon 22
GH - Ghana 22
NO - Norvegia 22
NZ - Nuova Zelanda 22
TW - Taiwan 22
AL - Albania 21
BO - Bolivia 21
BW - Botswana 21
IL - Israele 21
TZ - Tanzania 21
AU - Australia 20
BG - Bulgaria 20
CD - Congo 20
DJ - Gibuti 20
GE - Georgia 20
GN - Guinea 20
IR - Iran 20
Totale 15.595
Salva come PNG Salva come JPEG
Città #
Fairfield 1.148
Singapore 886
Ashburn 873
San Jose 771
Hong Kong 502
Woodbridge 461
Houston 436
Seattle 432
Cambridge 375
Wilmington 298
Chandler 220
Ann Arbor 198
Beijing 189
Ho Chi Minh City 170
San Diego 126
Hanoi 122
Los Angeles 120
Boardman 117
Bytom 112
Medford 87
Princeton 86
Santa Clara 82
Lauterbourg 81
Helsinki 79
Des Moines 68
New York 62
Tokyo 62
Amsterdam 59
Chicago 55
Munich 51
Dong Ket 49
Padova 48
São Paulo 46
Hefei 45
Nanjing 42
Nuremberg 38
Council Bluffs 36
Tashkent 36
Da Nang 35
Seoul 35
Baghdad 29
Dublin 29
Johannesburg 29
Orem 28
Maputo 27
Addis Ababa 26
Amman 26
Milan 26
Roxbury 26
Tripoli 26
Frankfurt am Main 25
Istanbul 25
Abidjan 24
Bridgetown 23
Chennai 23
Cotonou 23
Dakar 23
Guangzhou 23
Haiphong 23
Kampala 23
Jeddah 22
Panama City 22
The Dalles 22
Dushanbe 21
Libreville 21
Rome 21
Vienna 21
Accra 20
Baku 20
Bishkek 20
Buffalo 20
Kinshasa 20
Nairobi 20
Riga 20
Rio de Janeiro 20
Shenyang 20
Asunción 19
Bareggio 19
Nouakchott 19
Noumea 19
Bamako 18
Conakry 18
Luanda 18
Quito 18
Riyadh 18
Vientiane 18
Warsaw 18
Yerevan 18
Antananarivo 17
Bangkok 17
Dallas 17
Lappeenranta 17
Niamey 17
Praia 17
Ulan Bator 17
Biên Hòa 16
Havana 16
Hải Dương 16
Mamoudzou 16
Managua 16
Totale 9.994
Salva come PNG Salva come JPEG
Nome #
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 325
[Prevalence and risk factors for bacteriuria in patients with cirrhosis] 310
Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics 290
Detection of in vivo hepatitis B virus surface antigen mutations - a comparison of four routine screening assays 280
AISF position paper on HCV in immunocompromised patients 278
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 250
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study 244
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study 232
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 232
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients 230
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 221
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and Delta cohort 219
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 216
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study (PLoS ONE (2017) 12: 2 (e0172159) DOI: 10.1371/journal.pone.0172159) 215
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 214
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 208
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 204
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 201
[Cutaneous myiasis from Cordylobia anthropophaga in a traveller returning from Senegal: a case study] 198
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 190
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients 189
Waiting list mortality and 5-year transplant survival benefit of patients with MASLD: An Italian liver transplant registry study 188
The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma 187
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 185
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D 182
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir 180
Fever of unknown origin (FUO): which are the factors influencing the final diagnosis? A 2005-2015 systematic review 179
A prospective study of direct-acting antiviral effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort 179
Active recruitment strategy in disadvantaged immigrant populations improves the identification of human immunodeficiency but not of hepatitis B or C virus infections 177
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study 177
Impact of antigen test target failure and testing strategies on the transmission of SARS-CoV-2 variants 176
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 175
Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas 175
Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2+ 175
Hepatitis C Virus Clearance in Older Adults 174
Different changes in mitochondrial apoptotic pathway in lymphocytes and granulocytes in cirrhotic patients with sepsis 173
VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS 173
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 171
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 171
Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP) 168
Treatment of chronic hepatitis due to Hepatitis B with Delta virus coinfection 168
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 167
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis 165
Liver transplantation for t2 hepatocellular carcinoma during the covid-19 pandemic: A novel model balancing individual benefit against healthcare resources 165
Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology 163
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort 162
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 162
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 161
Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications 161
Cutaneous manifestations in a series of 417 patients with SARS-CoV-2 infection: epidemiological and clinical correlates of chilblain like lesions 158
Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency 157
Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy 156
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 155
Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy 155
Hepatitis c late relapse in patients with directly acting antiviral- related sustained virological response at week 12 151
An increase in the levels of middle surface antigen characterizes patients developing hbv-driven liver cancer despite prolonged virological suppression 151
Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort 151
Circulating Genotypes of Hepatitis C Virus in Italian Patients before and after the Application of Wider Access Criteria to HCV Treatment 150
Interleukin-28B genetic variants in untreated Italian HCV-infected patients: A multicentre study 149
Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance 149
Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers 148
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues 147
The present profile of chronic hepatitis B virus infection highlights future challenges: An analysis of the Multicenter Italian MASTER-B cohort 147
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 146
Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV) 144
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy 143
Hepatitis delta infection in Italian patients: towards the end of the story? 143
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy 143
Influenza vaccination in patients with cirrhosis and in liver transplant recipients 142
Intermediate and Advanced Hepatocellular Carcinoma Management in four Italian Centers: Patterns of Treatment and Costs 142
Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment 142
Changing indications for liver transplant: slow decline of hepatitis viruses in Italy 142
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort 141
Sunscreen ingredients in plasma: a threat for drug-drug interactions and toxicity among patients living with HIV? 141
Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy 139
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort 138
Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study 138
Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? 137
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 135
CD8+ T cells specific to apoptosis-associated epitopes are expanded in patients with chronic HBV infection and fibrosis 135
Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey 135
HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years 129
Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B 129
Individualized treatment of genotype 1 Naïve patients: An Italian multicenter field practice experience 127
Recent breakthroughs in the treatment of chronic hepatitis Delta 126
Letter Comment to: Which saint to pray for fighting against COVID? A short survey. By Perciaccante A et al. 124
Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2+ 124
Is spleen circulation impaired in systemic sclerosis and what is the role of liver fibrosis? 123
Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma 121
Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population 120
Prophylaxis of hepatitis B virus (HBV) re-infection in liver transplantation: Is the reappearance of hepatitis B surface antigen (HBsAg) significant? 119
Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection 118
Forecasting Hepatitis C liver disease burden on real life data. Does the hidden iceberg matter to reach the elimination goals? 112
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin 110
Increased liver stiffness in idiopathic pulmonary fibrosis: a pilot study 99
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 91
Salvage therapy with tenofovir followed by adefovir maintenance in a cirrhotic patient with a lamivudine resistant HBV flare 86
Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study 83
Letter: clinical outcomes of patients with hepatitis D infection in the liver transplant setting-authors' reply 78
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 59
Totale 16.513
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.117
article - articoli 45.214
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.331
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021280 0 0 0 0 0 0 0 0 0 0 189 91
2021/20221.290 78 175 145 73 68 63 90 136 90 32 110 230
2022/2023607 157 46 35 56 101 58 11 37 71 2 27 6
2023/2024478 16 61 41 67 40 35 51 16 32 14 40 65
2024/20252.079 8 135 64 79 194 50 108 151 205 144 361 580
2025/20268.725 370 767 1.292 1.533 653 388 1.051 856 931 515 369 0
Totale 16.656